{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T23:29:22Z","timestamp":1793316562624,"version":"4.5.0"},"reference-count":40,"publisher":"American Medical Association (AMA)","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Oncol"],"published-print":{"date-parts":[[2026,9,1]]},"abstract":"\n Importance<\/jats:title>\n Transarterial chemoembolization (TACE) is the standard of care for liver-confined hepatocellular carcinoma (HCC) that is not amenable to curative treatment; however, TACE has demonstrated unsatisfactory survival benefits.<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n To evaluate whether combining TACE with subsequent thermal ablation improves clinical outcomes compared with TACE alone in patients with liver-confined unresectable HCC.<\/jats:p>\n <\/jats:sec>\n \n Design, Setting, and Participants<\/jats:title>\n The open-label, phase 3 TORCH randomized clinical trial was conducted from May 2015 to August 2024 at 2 tertiary medical centers in China. Patients with Barcelona Clinic Liver Cancer stage B HCC were enrolled. The data cutoff was October 31, 2025.<\/jats:p>\n <\/jats:sec>\n \n Interventions<\/jats:title>\n Patients were randomly assigned (1:1) to receive either TACE combined with subsequent selective radiofrequency ablation (TACE-ablation) or TACE alone.<\/jats:p>\n <\/jats:sec>\n \n Main Outcomes and Measures<\/jats:title>\n The primary end point was progression-free survival (PFS), assessed per Response Evaluation Criteria in Solid Tumors (RECIST), version 1.1. Secondary end points included overall survival (OS), treatment response and PFS per modified RECIST, untreatable PFS, and safety.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n Among 241 patients included in the intention-to-treat population, 121 received TACE-ablation (median [IQR] age, 59.0 [51.0-66.0] years; 108 [89.3%] male), and 120 received TACE alone (mean [IQR] age, 58.0 [50.0-64.0]; 106 [88.3] male). The number of patients with 6-and-12 tumor burden scores of lower than 6, 6 to 12, and more than 12 points were 34 (28.1%), 79 (65.3%), and 8 (6.6%) in the TACE-ablation group and 31 (25.8%), 76 (63.3%), and 13 (10.8%) in the TACE alone group, respectively. At the data cutoff, the median PFS per RECIST, version 1.1, was 17.7 months (95% CI, 11.4-23.1 months) in the TACE-ablation group vs 7.3 months (95% CI, 6.4-10.4 months) in the TACE alone group (hazard ratio [HR], 0.47; 95% CI, 0.34-0.65;\n P<\/jats:italic>\n \u2009&amp;lt;\u2009.001). TACE-ablation also resulted in statistically significant prolonged untreatable PFS compared with TACE (35.1 months vs 12.3 months; HR, 0.40; 95% CI, 0.27-0.58;\n P<\/jats:italic>\n \u2009&amp;lt;\u2009.001). Median OS was 88.6 months (95% CI, 43.1 months to not estimable) with TACE-ablation and 35.1 months (95% CI, 25.4-45.5 months) with TACE alone (HR, 0.50; 95% CI, 0.34-0.73;\n P<\/jats:italic>\n \u2009&amp;lt;\u2009.001). Clinically meaningful improvements in both PFS and OS were observed in patients with low to moderate tumor burden scores (\u22646 and 6-12 points). Grade 3 and 4 treatment-related adverse events occurred in 23 patients (23.2%) in the TACE-ablation group and 24 (18.3%) in the TACE alone group.\n <\/jats:p>\n <\/jats:sec>\n \n Conclusions and Relevance<\/jats:title>\n In this phase 3 randomized clinical trial, TACE combined with subsequent thermal ablation demonstrated superior survival outcomes than TACE alone in patients with liver-confined unresectable HCC. Sequential TACE-ablation could serve as a feasible treatment option for such patients.<\/jats:p>\n <\/jats:sec>\n \n Trial Registration<\/jats:title>\n \n ClinicalTrials.gov Identifier:\n NCT02435953<\/jats:ext-link>\n <\/jats:p>\n <\/jats:sec>","DOI":"10.1001\/jamaoncol.2026.2366","type":"journal-article","created":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T15:30:32Z","timestamp":1785425432000},"page":"980","source":"Crossref","is-referenced-by-count":4,"title":["Transarterial Chemoembolization Plus Thermal Ablation in Unresectable Hepatocellular Carcinoma"],"prefix":"10.1001","volume":"12","author":[{"given":"Ning","family":"Lyu","sequence":"first","affiliation":[{"name":"Department of Interventional Oncology, Liver Cancer Study and Service Group, State Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer Center, Guangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun-Zhe","family":"Yi","sequence":"additional","affiliation":[{"name":"Department of Interventional Oncology, Liver Cancer Study and Service Group, State Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer Center, Guangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin-Tong","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Interventional Oncology, Liver Cancer Study and Service Group, State Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer Center, Guangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi-Min","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Interventional Oncology, Liver Cancer Study and Service Group, State Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer Center, Guangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Pan","sequence":"additional","affiliation":[{"name":"Department of Interventional Radiology, The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lu-Wen","family":"Mu","sequence":"additional","affiliation":[{"name":"Department of Interventional Radiology, The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Song","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Interventional Oncology, Liver Cancer Study and Service Group, State Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer Center, Guangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiong-Liang","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Interventional Oncology, Liver Cancer Study and Service Group, State Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer Center, Guangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Interventional Oncology, Liver Cancer Study and Service Group, State Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer Center, Guangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gen-Jun","family":"Tan","sequence":"additional","affiliation":[{"name":"Department of Interventional Oncology, Liver Cancer Study and Service Group, State Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer Center, Guangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Nan","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Interventional Oncology, Liver Cancer Study and Service Group, State Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer Center, Guangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zu-Qing","family":"Gao","sequence":"additional","affiliation":[{"name":"Department of Interventional Oncology, Liver Cancer Study and Service Group, State Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer Center, Guangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zi-Xi","family":"Ou-Yang","sequence":"additional","affiliation":[{"name":"Department of Interventional Oncology, Liver Cancer Study and Service Group, State Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer Center, Guangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei-Jie","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Interventional Oncology, Liver Cancer Study and Service Group, State Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer Center, Guangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Jia","family":"Song","sequence":"additional","affiliation":[{"name":"Department of Interventional Oncology, Liver Cancer Study and Service Group, State Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer Center, Guangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hai-Jing","family":"Deng","sequence":"additional","affiliation":[{"name":"Department of Interventional Oncology, Liver Cancer Study and Service Group, State Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer Center, Guangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meng","family":"He","sequence":"additional","affiliation":[{"name":"Department of Interventional Oncology, Liver Cancer Study and Service Group, State Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer Center, Guangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi-Quan","family":"Jiang","sequence":"additional","affiliation":[{"name":"Department of Interventional Oncology, Liver Cancer Study and Service Group, State Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer Center, Guangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi-Feng","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Interventional Oncology, Liver Cancer Study and Service Group, State Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer Center, Guangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ji-Bin","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Clinical Research, State Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer Center, Guangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming","family":"Shi","sequence":"additional","affiliation":[{"name":"Department of Liver Surgery, Liver Cancer Study and Service Group, State Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer Center, Guangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min-Shan","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Liver Surgery, Liver Cancer Study and Service Group, State Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer Center, Guangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming","family":"Zhao","sequence":"additional","affiliation":[{"name":"Department of Interventional Oncology, Liver Cancer Study and Service Group, State Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer Center, Guangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"3","key":"coi260036r1","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1016\/j.jhep.2025.10.020","article-title":"BCLC strategy for prognosis prediction and treatment recommendations: the 2026 update.","volume":"84","author":"Reig","year":"2026","journal-title":"J Hepatol"},{"issue":"6","key":"coi260036r2","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1159\/000546574","article-title":"China liver cancer guidelines for the diagnosis and treatment of hepatocellular carcinoma (2024 edition).","volume":"14","author":"Zhou","year":"2025","journal-title":"Liver Cancer"},{"issue":"6","key":"coi260036r3","doi-asserted-by":"publisher","first-page":"498","DOI":"10.3322\/caac.70018","article-title":"Advances in the treatment of hepatocellular carcinoma: an overview of the current and evolving therapeutic landscape for clinicians.","volume":"75","author":"Moris","year":"2025","journal-title":"CA Cancer J Clin"},{"issue":"3","key":"coi260036r4","doi-asserted-by":"publisher","DOI":"10.1016\/j.engmed.2024.100037","article-title":"Transarterial chemoembolization for hepatocellular carcinoma: treatment algorithm proposed by Chinese College of Interventionalists (CCI).","volume":"1","author":"Zhu","year":"2024","journal-title":"EngMedicine"},{"issue":"2","key":"coi260036r5","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1053\/jhep.2003.50047","article-title":"Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival.","volume":"37","author":"Llovet","year":"2003","journal-title":"Hepatology"},{"key":"coi260036r6","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2024.122540","article-title":"Molecular mechanisms of TACE refractoriness: directions for improvement of the TACE procedure.","volume":"342","author":"Li","year":"2024","journal-title":"Life Sci"},{"issue":"1","key":"coi260036r7","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/s44326-025-00049-y","article-title":"Intratumoral vessel caliber and microvascular density in hepatocellular carcinoma.","volume":"12","author":"Behee","year":"2025","journal-title":"J Med Imaging Intervent Radiol"},{"issue":"3","key":"coi260036r8","doi-asserted-by":"publisher","first-page":"E100","DOI":"10.1111\/hepr.12534","article-title":"Diameter of main tumor feeding artery of a hepatocellular carcinoma: measurement at the entry site into the nodule.","volume":"46","author":"Irie","year":"2016","journal-title":"Hepatol Res"},{"issue":"5","key":"coi260036r9","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1111\/jgh.12873","article-title":"Transarterial chemoembolization aggravated peritumoral fibrosis via hypoxia-inducible factor-1a dependent pathway in hepatocellular carcinoma.","volume":"30","author":"Qu","year":"2015","journal-title":"J Gastroenterol Hepatol"},{"issue":"1","key":"coi260036r10","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1007\/s44178-023-00057-6","article-title":"Recent highlights of cancer immunotherapy.","volume":"2","author":"Fan","year":"2023","journal-title":"Holist Integr Oncol"},{"issue":"3","key":"coi260036r11","doi-asserted-by":"publisher","DOI":"10.1016\/j.engmed.2025.100091","article-title":"Transarterial intervention therapy plus systemic therapy for unresectable hepatocellular carcinoma: a systematic review and meta-analysis.","volume":"2","author":"Liu","year":"2025","journal-title":"EngMedicine"},{"issue":"10474","key":"coi260036r12","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1016\/S0140-6736(24)02551-0","article-title":"Durvalumab with or without bevacizumab with transarterial chemoembolisation in hepatocellular carcinoma (EMERALD-1): a multiregional, randomised, double-blind, placebo-controlled, phase 3 study.","volume":"405","author":"Sangro","year":"2025","journal-title":"Lancet"},{"issue":"10474","key":"coi260036r13","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/S0140-6736(24)02575-3","article-title":"Transarterial chemoembolisation combined with lenvatinib plus pembrolizumab versus dual placebo for unresectable, non-metastatic hepatocellular carcinoma (LEAP-012): a multicentre, randomised, double-blind, phase 3 study.","volume":"405","author":"Kudo","year":"2025","journal-title":"Lancet"},{"key":"coi260036r14","doi-asserted-by":"publisher","first-page":"S62","DOI":"10.1016\/j.annonc.2025.05.542","article-title":"LBA2 TALENTACE: a phase III, open-label, randomized study of on-demand transarterial chemoembolization (TACE) combined with atezolizumab + bevacizumab (Atezo+Bev) or on-demand TACE alone in patients with systemically untreated, intermediate-to-high burden unresectable hepatocellular carcinoma (uHCC).","volume":"36","author":"Dong","year":"2025","journal-title":"Ann Oncol"},{"issue":"2","key":"coi260036r15","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1002\/ueg2.12554","article-title":"Locoregional therapies for hepatocellular carcinoma: the current status and future perspectives.","volume":"12","author":"Chen","year":"2024","journal-title":"United European Gastroenterol J"},{"issue":"5","key":"coi260036r16","doi-asserted-by":"publisher","first-page":"661","DOI":"10.21037\/hbsn-21-260","article-title":"Clinical practice of transarterial chemoembolization for hepatocellular carcinoma: consensus statement from an international expert panel of International Society of Multidisciplinary Interventional Oncology (ISMIO).","volume":"10","author":"Lu","year":"2021","journal-title":"Hepatobiliary Surg Nutr"},{"issue":"2","key":"coi260036r17","doi-asserted-by":"publisher","DOI":"10.1148\/radiol.241096","article-title":"Transarterial chemoembolization with radiofrequency ablation versus surgical resection for small late-recurrence hepatocellular carcinoma.","volume":"314","author":"Zhang","year":"2025","journal-title":"Radiology"},{"issue":"1","key":"coi260036r18","doi-asserted-by":"publisher","DOI":"10.3322\/caac.70051","article-title":"Interventional oncology: a primer for clinicians on the role of ablation and embolization for solid tumors.","volume":"76","author":"Abdelsalam","year":"2026","journal-title":"CA Cancer J Clin"},{"issue":"7","key":"coi260036r19","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1111\/j.1872-034X.2010.00673.x","article-title":"Management of hepatocellular carcinoma: report of Consensus Meeting in the 45th Annual Meeting of the Japan Society of Hepatology (2009).","volume":"40","author":"Arii","year":"2010","journal-title":"Hepatol Res"},{"issue":"4","key":"coi260036r20","doi-asserted-by":"publisher","first-page":"583","DOI":"10.3350\/cmh.2022.0294","article-title":"2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma.","volume":"28","author":"Korean Liver Cancer Association (KLCA) and National Cancer Center (NCC) Korea","year":"2022","journal-title":"Clin Mol Hepatol"},{"issue":"22","key":"coi260036r22","doi-asserted-by":"publisher","first-page":"1998","DOI":"10.1001\/jama.2025.4347","article-title":"CONSORT 2025 Statement: Updated Guideline for Reporting Randomized Trials.","volume":"333","author":"Hopewell","year":"2025","journal-title":"JAMA"},{"issue":"10","key":"coi260036r23","doi-asserted-by":"publisher","first-page":"2717","DOI":"10.1016\/j.ejrad.2011.10.023","article-title":"CT-guided radiofrequency ablation after with transarterial chemoembolization in treating unresectable hepatocellular carcinoma with long overall survival improvement.","volume":"81","author":"Zhao","year":"2012","journal-title":"Eur J Radiol"},{"issue":"9","key":"coi260036r24","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1016\/j.jvir.2021.06.008","article-title":"Hepatic artery infusion chemotherapy using fluorouracil, leucovorin, and oxaliplatin versus transarterial chemoembolization as initial treatment for locally advanced hepatocellular carcinoma: a propensity score-matching analysis.","volume":"32","author":"Li","year":"2021","journal-title":"J Vasc Interv Radiol"},{"issue":"3","key":"coi260036r25","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1001\/jama.2021.9941","article-title":"Guidelines for reporting trial protocols and completed trials modified due to the COVID-19 pandemic and other extenuating circumstances: the CONSERVE 2021 statement.","volume":"326","author":"Orkin","year":"2021","journal-title":"JAMA"},{"issue":"4","key":"coi260036r26","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1056\/NEJMoa0708857","article-title":"Sorafenib in advanced hepatocellular carcinoma.","volume":"359","author":"Llovet","year":"2008","journal-title":"N Engl J Med"},{"issue":"10064","key":"coi260036r27","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/S0140-6736(16)32453-9","article-title":"Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial.","volume":"389","author":"Bruix","year":"2017","journal-title":"Lancet"},{"key":"coi260036r28","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanepe.2025.101408","article-title":"Disparities in access to systemic therapies for patients with hepatocellular carcinoma: an analysis from the International Liver Cancer Association.","volume":"57","author":"Allaire","year":"2025","journal-title":"Lancet Reg Health Eur"},{"issue":"2","key":"coi260036r29","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2021.0037","article-title":"Cost-effectiveness of atezolizumab plus bevacizumab vs sorafenib as first-line treatment of unresectable hepatocellular carcinoma.","volume":"4","author":"Su","year":"2021","journal-title":"JAMA Netw Open"},{"issue":"1","key":"coi260036r30","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1007\/s00270-009-9711-7","article-title":"Prospective randomized study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma: results of the PRECISION V study.","volume":"33","author":"Lammer","year":"2010","journal-title":"Cardiovasc Intervent Radiol"},{"issue":"2","key":"coi260036r31","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1038\/bjc.2014.199","article-title":"Randomised controlled trial of doxorubicin-eluting beads vs conventional chemoembolisation for hepatocellular carcinoma.","volume":"111","author":"Golfieri","year":"2014","journal-title":"Br J Cancer"},{"issue":"2","key":"coi260036r32","doi-asserted-by":"publisher","first-page":"243","DOI":"10.4103\/jcrt.JCRT_504_19","article-title":"A comparison between drug-eluting bead-transarterial chemoembolization and conventional transarterial chemoembolization in patients with hepatocellular carcinoma: a meta-analysis of six randomized controlled trials.","volume":"16","author":"Wang","year":"2020","journal-title":"J Cancer Res Ther"},{"issue":"2","key":"coi260036r33","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1007\/s00535-017-1374-6","article-title":"Transarterial chemoembolization with miriplatin vs. epirubicin for unresectable hepatocellular carcinoma: a phase III randomized trial.","volume":"53","author":"Ikeda","year":"2018","journal-title":"J Gastroenterol"},{"key":"coi260036r34","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/j.ejca.2021.08.027","article-title":"Arterial chemoembolisation with cisplatin versus epirubicin for hepatocellular carcinoma (ACE 500 study): a multicentre, randomised controlled phase 2\/3 trial.","volume":"157","author":"Aramaki","year":"2021","journal-title":"Eur J Cancer"},{"issue":"6","key":"coi260036r35","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.1007\/s00270-012-0352-x","article-title":"Prospective evaluation of transcatheter arterial chemoembolization (TACE) with multiple anti-cancer drugs (epirubicin, cisplatin, mitomycin c, 5-fluorouracil) compared with TACE with epirubicin for treatment of hepatocellular carcinoma.","volume":"35","author":"Sahara","year":"2012","journal-title":"Cardiovasc Intervent Radiol"},{"issue":"6","key":"coi260036r36","doi-asserted-by":"publisher","first-page":"1172","DOI":"10.1136\/gutjnl-2016-312629","article-title":"Percutaneous cooled-probe microwave versus radiofrequency ablation in early-stage hepatocellular carcinoma: a phase III randomised controlled trial.","volume":"66","author":"Yu","year":"2017","journal-title":"Gut"},{"issue":"5","key":"coi260036r37","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1016\/S2468-1253(18)30029-3","article-title":"Efficacy of microwave ablation versus radiofrequency ablation for the treatment of hepatocellular carcinoma in patients with chronic liver disease: a randomised controlled phase 2 trial.","volume":"3","author":"Vietti Violi","year":"2018","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"3","key":"coi260036r38","doi-asserted-by":"publisher","first-page":"562","DOI":"10.21037\/jgo.2019.01.34","article-title":"Percutaneous radiofrequency versus microwave ablation for management of hepatocellular carcinoma: a randomized controlled trial.","volume":"10","author":"Kamal","year":"2019","journal-title":"J Gastrointest Oncol"},{"issue":"8","key":"coi260036r39","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1016\/j.hpb.2020.01.008","article-title":"Prospective double-blinded randomized controlled trial of microwave versus radiofrequency ablation for hepatocellular carcinoma (McRFA trial).","volume":"22","author":"Chong","year":"2020","journal-title":"HPB (Oxford)"},{"issue":"1","key":"coi260036r40","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhepr.2024.101269","article-title":"Microwave ablation vs. single-needle radiofrequency ablation for the treatment of HCC up to 4 cm: a randomized-controlled trial.","volume":"7","author":"Sugimoto","year":"2024","journal-title":"JHEP Rep"},{"key":"coi260036r21","volume-title":"Guidelines for Hepatocellular Carcinoma","author":"Chinese Society of Clinical Oncology","year":"2024"}],"container-title":["JAMA Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamaoncology\/articlepdf\/2852203\/jamaoncology_lyu_2026_oi_260036_1789560624.13314.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T15:00:46Z","timestamp":1789657246000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamaoncology\/fullarticle\/2852203"}},"subtitle":["The Phase 3 TORCH Randomized Clinical Trial"],"short-title":[],"issued":{"date-parts":[[2026,9,1]]},"references-count":40,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamaoncol.2026.2366","relation":{},"ISSN":["2374-2437"],"issn-type":[{"value":"2374-2437","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9,1]]}}}